Verdermica to hold a conference call to discuss 12-month long-term results from the Phase 3 '302' clinical trial of VDPHL01 in men with mild to moderate pattern hair loss -. Company announcement - FT.com.
Verdermica to hold a conference call to discuss 12-month long-term results from the Phase 3 '302' clinical trial of VDPHL01 in men with mild to moderate pattern hair loss -. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in